GRI Bio reports Phase 2a IPF biomarker and safety data
GRI Bio said Phase 2a translational biomarker and safety data for GRI-0621 showed a placebo-adjusted Week 12 FVC gain overall and on background antifibrotic therapy.
Key Highlights:Original SEC Filing: GRI Bio, Inc. [ GRI ] - 8-K - Sep. 08, 2026This is an AI-powered summary. I…